Biodefense start-up companies have an abundance of options when seeking funding.
Sandy Weinberg, PhD
Advertisement
Sandy Weinberg, PhD, is an associate professor of healthcare management at Clayton State University
Articles by Sandy Weinberg, PhD
Advertisement
Latest Updated Articles
Funding Biodefense Vaccine DevelopmentApril 1st 2009
Advertisement
Advertisement
Trending on BioPharm International
1
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
2
FDA Reportedly Pauses National Priority Voucher Pilot and Pauses CRL Publication
3
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
4
FDA Clears IND for Biolojic’s BD200, the First AI-Designed Multibody ADC to Enter Clinical Trials
5